When the victims of serious and irreversible drug-induced harms seek compensation for their injuries, they hit a brick wall. Pharmaceutical companies are protected by European law and it is extremely difficult to prove their liability in court. In France, the "modernisation of our health system" law will constitute an advance for some, but probably not most, of these victims through the introduction of class actions for health-related claims. Major obstacles still remain: establishing a causal link between the drug and the adverse effect is difficult, the burden of proof lies with the victim, a high degree of disability is required, etc.
展开▼
